Denali Therapeutics (DNLI) Retained Earnings (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Retained Earnings of -$682000.0 for Q1 2026, down 100.02% year-over-year from $2.8 billion in Q1 2025, and down 200.0% quarter-over-quarter from $682000.0 in Q4 2025.
Denali Therapeutics (DNLI) Retained Earnings (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Retained Earnings for 10 consecutive years, with -$682000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 100.02% year-over-year to -$682000.0; the TTM figure through Mar 2026 stood at -$682000.0 (down 100.02% YoY), while the FY2025 annual figure was $682000.0, up 100.04% from the prior year.
- Retained Earnings eased to -$682000.0 in Q1 2026 per DNLI's latest filing, from $682000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $2.8 billion in Q1 2025 and bottomed at -$1.9 billion in Q3 2025.
- Historically, Retained Earnings has averaged -$430.0 million across 5 years, with a median of -$872.3 million in 2022.
- On a YoY basis, Retained Earnings climbed as much as 705203.45% in 2022 and fell as far as 167329.75% in 2022.
- Denali Therapeutics' Retained Earnings stood at -$971.0 million in 2022, then decreased by 14.96% to -$1.1 billion in 2023, then sank by 37.88% to -$1.5 billion in 2024, then soared by 100.04% to $682000.0 in 2025, then slumped by 200.0% to -$682000.0 in 2026.
- Business Quant data shows DNLI's Retained Earnings at -$682000.0 in Q1 2026, $682000.0 in Q4 2025, and -$1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 3.14 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.14 Bn |
| Mar 31, 2026 | -682,000.00 |
| Dec 31, 2025 | 682,000.00 |
| Sep 30, 2025 | -1.92 Bn |
| Jun 30, 2025 | -1.80 Bn |
| Mar 31, 2025 | 2.79 Bn |
| Dec 31, 2024 | -1.54 Bn |
| Sep 30, 2024 | -1.42 Bn |
| Jun 30, 2024 | -2.66 Mn |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | -1.12 Bn |
| Sep 30, 2023 | -996.74 Mn |
| Jun 30, 2023 | -1.44 Mn |
| Mar 31, 2023 | -1.08 Bn |
| Dec 31, 2022 | -970.99 Mn |
| Sep 30, 2022 | -872.31 Mn |
| Jun 30, 2022 | -12.27 Mn |
| Mar 31, 2022 | 1.64 Bn |
| Dec 31, 2021 | -645.00 Mn |
| Sep 30, 2021 | -521,000.00 |